stent

SOLACI-CACI 2021 Preliminary Agenda

Check out the main topics of the upcoming SOLACI-CACI 2021 Congress. Save the Date! &nbsp; Special Session About the COVID-19 Pandemic &nbsp; Managing Cardiovascular disease and Cath Lab during the COVID-19 Pandemic Live Case Transmissions Coronary and Structural cases performed by distinguished international and national operators. Coronary Track &nbsp; Myocardial Infarction, Left Main session, Complex<a href="https://solaci.org/en/2020/06/09/solaci-caci-2021-preliminary-agenda/" title="Read more" >...</a>

Engrosamiento e inmovilidad de las valvas en el Evolut Low Risk

Leaflet Thickening and Immobility in Evolut Low Risk

Leaflet thickening and immobility caused by thrombosis have been reported for both surgical and transcatheter bioprostheses. This phenomenon is diagnosed through hypoattenuation, thickening, and lack of motion, as observed through computed tomography (CT) imaging. The incidence and, especially, the clinical implications of this phenomenon remain unclear, but they are of great interest, particularly in a<a href="https://solaci.org/en/2020/06/09/leaflet-thickening-and-immobility-in-evolut-low-risk/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

TAVR: Balloon-Expandable or Self-Expanding Valves, Which Is the Answer?

Courtesy of Dr. Carlos&nbsp;Fava. Transcatheter aortic valve replacement (TAVR) has shown benefit and is currently moving towards low-risk patients, as well as bicuspid aortic valves and (to a lower extent) aortic regurgitation. However, we must ponder on which valve should be used on each patient: balloon-expandable (BE) or self-expanding (SE) valve? They represent different technologies<a href="https://solaci.org/en/2020/06/03/tavr-balloon-expandable-or-self-expanding-valves-which-is-the-answer/" title="Read more" >...</a>

Balancear el riesgo de sangrado vs trombótico para definir el tiempo de doble antiagregación

Antiaggregation vs. Anticoagulation after Peripheral PCI

The truth is this question has no clear answer and what with do with peripheral stenting is transfer the evidence we have on coronary stenting, given the lack of standards and poor reporting on antithrombotic therapy outcomes in randomized studies on endovascular intervention.&nbsp; Heterogeneity is worse when it comes to venous territory. Some time ago<a href="https://solaci.org/en/2020/06/01/antiaggregation-vs-anticoagulation-after-peripheral-pci/" title="Read more" >...</a>

TAVI: Balón expandible o autoexpandible ¿Cuál es la respuesta?

In Search of the Optimal Depth for Self-Expandable Valves

Despite the use of the different imaging approaches to calculating implantation depth, optimal depth is reached only 30% of the time. Multiple imaging does not offer a uniform perspective and therefore influence reporting.&nbsp; Basically, we do not have a clear idea of what constitutes optimal depth on a case by case basis and, what is<a href="https://solaci.org/en/2020/05/20/in-search-of-the-optimal-depth-for-self-expandable-valves/" title="Read more" >...</a>

Historia natural de la infección asintomática por COVID-19

Management of Infarction During the COVID-19 Pandemic

Patients with cardiovascular disease infected with COVID-19 are at a particular risk for morbidity and mortality. In any case, it should be noted that most patients requiring cardiovascular care due to ischemic heart disease, peripheral vascular disease, or structural heart disease are not infected. Being prepared to face this pandemic is as important as guaranteeing<a href="https://solaci.org/en/2020/05/14/management-of-infarction-during-the-covid-19-pandemic/" title="Read more" >...</a>

Carotídeas asintomáticas ¿Tenemos todas las respuestas?

Asymptomatic Carotid Artery Stenosis: Do We Have All the Answers?

Advancements in therapies to reduce the impact of stroke in asymptomatic carotid artery stenosis have been hard to come by over the last decade. Several points of disagreement among published randomized trials prevented their information from being integrated into daily clinical practice. However, over the past 5&nbsp;years, there has been some alignment, allowing for this<a href="https://solaci.org/en/2020/05/11/asymptomatic-carotid-artery-stenosis-do-we-have-all-the-answers/" title="Read more" >...</a>

struts ultrafinos

BIOFLOW V: Ultrathin Struts Confirm their Benefits

For several years we have been testing new devices that have introduce changes with respect to their predecessors in the hope they will bring clinical benefits.&nbsp; And so, the different generations of drug eluting stents came about (DES) even though we found ourselves stuck in the second generation, with the classical everolimus eluting stents. All<a href="https://solaci.org/en/2020/05/07/bioflow-v-ultrathin-struts-confirm-their-benefits/" title="Read more" >...</a>

implante de la valvula aortica transcateter

TAVR Reaches Low-Risk Patients with Bicuspid Valves

Transcatheter aortic valve replacement (TAVR) seems to be safe in low-risk patients with bicuspid aortic valve stenosis. Their hospital length of stay was very short, with zero mortality, and zero disabling stroke. Subclinical leaflet thrombosis and device durability are still unknown. The United States Food and Drug Administration (FDA) approved TAVR for low-risk patients. However,<a href="https://solaci.org/en/2020/04/27/tavr-reaches-low-risk-patients-with-bicuspid-valves/" title="Read more" >...</a>

Doctor con tabletas de aspirinas

Are Non-Culprit Lesions Really Innocent?

In recent times, a lot has been said about reducing the duration or intensity of antiplatelet therapy following percutaneous coronary intervention (PCI) regardless initial indications. All evidence in support of these arguments might be failing to show the risk of non-culprit lesion events in patients with acute coronary syndromes (ACS). Potent and prolonged antithrombotic therapies<a href="https://solaci.org/en/2020/04/22/are-non-culprit-lesions-really-innocent/" title="Read more" >...</a>

Top